GlassScriptPhysician profile
Richard D Shusterman
NPI 1043250202
$194,017.43
in general payments reported to CMS, 2019-2025
43 companies · $2,119 in 2025
The $2,119 reported for 2025 was more than what 77% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $25K · 2021: $28K · 2022: $36K · 2023: $39K · 2024: $31K · 2025: $2,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $61K · Food and Beverage: $8,676 · Travel and Lodging: $1,205 · Education: $315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $61,425.00 |
| Food and Beverage | $8,676.23 |
| Travel and Lodging | $1,204.53 |
| Education | $314.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $178,158.89 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $4,523.05 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Viiv Healthcare Company | $3,514.30 | 2019 | |
| Jazz Pharmaceuticals INC. | $1,042.76 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $732.28 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Harmony Biosciences LLC | $593.90 | 2020-2025 | Wakix |
| Genentech USA, INC. | $586.42 | 2019-2025 | Xolair |
| Insmed, INC. | $555.11 | 2019-2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $444.32 | 2019-2025 | Dupixent |
| Genzyme Corporation | $404.62 | 2019-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $326.80 | 2023-2025 | Lumryz |
| Mylan Specialty L.P. | $283.07 | 2019-2024 | Yupelri |
| Amgen INC. | $266.38 | 2022-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $238.23 | 2019-2023 | |
| Edwards Lifesciences Corporation | $206.34 | 2023 | Sapien 3 Ultra Resilia |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $206.20 | 2019-2023 | Uptravi, Opsumit |
| Electromed, INC. | $174.33 | 2022-2025 | Smartvest |
| Philips North America LLC | $166.57 | 2019-2025 | Vest Therapy Und |
| Sunovion Pharmaceuticals INC. | $159.32 | 2019-2020 | |
| Verona Pharma, INC. | $157.68 | 2025 | Ohtuvayre |
| Axsome Therapeutics, INC. | $153.04 | 2022-2025 | Sunosi |
| Pfizer INC. | $140.89 | 2019-2025 | |
| Inspire Medical Systems, INC. | $133.21 | 2023-2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $107.30 | 2020-2023 | Aralast |
| Pulmonx Corporation | $66.30 | 2023-2025 | Zephyr Delivery Catheter, Chartis Catheter, Zephyr Endobronchial Valve |
| Grifols USA, LLC | $63.61 | 2020-2025 | Prolastin-C Liquid |
| Resmed Corp | $61.98 | 2019-2022 | |
| Advanced Respiratory, INC | $58.83 | 2019-2020 | |
| Kaleo, INC. | $56.41 | 2019-2021 | |
| Inogen, INC. | $55.79 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| United Therapeutics Corporation | $53.18 | 2024 | Tyvaso |
| Merck Sharp & Dohme LLC | $48.29 | 2019-2025 | |
| Vifor Pharma, INC. | $44.58 | 2025 | Zemaira |
| Teva Pharmaceuticals USA, INC. | $34.47 | 2019-2020 | |
| Circassia INC. | $30.08 | 2019 | |
| Ani Pharmaceuticals, INC. | $26.32 | 2023 | Purified Cortrophin Gel |
| Eisai INC. | $26.10 | 2020 | |
| Masimo Corporation | $23.37 | 2020 | |
| Shire North American Group INC | $22.30 | 2019 | |
| Viatris Specialty LLC | $20.83 | 2025 | Yupelri |
| Lilly USA, LLC | $19.26 | 2025 | Zepbound, Mounjaro |
| Idorsia Pharmaceuticals US INC | $15.81 | 2024 | Quviviq |
| Atricure, INC. | $14.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Shusterman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.